SCHEMBL5336835

SCHEMBL5336835

COc1cc(Nc2nc(C)nc3cc(Br)sc23)cc(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
FBP1 P09467 1/20 0.39
EGFR P00533 3/20 0.39
PDGFRB P09619 1/20 0.39
KDR P35968 1/20 0.39
CLK1 P49759 1/20 0.39
EPAS1 Q99814 1/20 0.39
LCK P06239 1/20 0.38
IGF1R P08069 1/20 0.37
PIK3CA P42336 2/20 0.37
CSNK2A1 P68400 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
LMNA P02545 2/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
BRAF P15056 1/20 0.36
TP53 P04637 2/20 0.36
MAPT P10636 2/20 0.36
DHFR P00374 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5312141 0.90 FBP1 (0.35) DYRK1ADYRK1BFBP1EGFRPDGFRB
SCHEMBL5334233 0.80 EGFR (0.53) DYRK1ADYRK1BEGFRKDRCLK1
SCHEMBL5455366 0.77 CSNK2A1 (0.46) DYRK1ADYRK1BEGFRPDGFRBKDR
SCHEMBL5335568 0.71 EGFR (0.46) DYRK1ADYRK1BEGFRCLK1LCK
SCHEMBL5314126 0.69 CSNK2A1 (0.39) DYRK1ADYRK1BEGFRPDGFRBKDR
SCHEMBL5480155 0.69 RAB9A (0.48) MAPTMEN1KMT2APOLB
SCHEMBL7127086 0.69 FLT1 (0.54) EGFRKDRSMN1; SMN2LMNAHTT
SCHEMBL14777496 0.68 EGFR (0.60) DYRK1ADYRK1BEGFRKDRCLK1
SCHEMBL22946708 0.68 SMN1; SMN2 (0.48) DYRK1ADYRK1BFBP1EGFRCLK1
SCHEMBL7124474 0.68 MAPT (0.56) DYRK1ADYRK1BEGFRKDRCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007056215-A9 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA INC (US) 2007-09-13 WO claimed
WO-2007056215-A2 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA, INC. (US) 2007-05-18 WO claimed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US claimed
WO-2007056215-A9 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA INC (US) 2007-09-13 WO disclosed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, API5 DYRK1A 3697/4885DYRK1B 3847/4885FBP1 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.